Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients

Abstract

BackgroundThe interleukin (IL)18 rs360719 CC genotype is associated with the development of antibodies to hepatitis B virus surface antigen (anti-HBs) in hemodialysis (HD) patients. IL18 shares biological properties with IL12 in promoting the T-hepler 1 (Th1) system. We studied whether polymorphisms in the IL12A 3` untranslated region (UTR) and IL12B 3`UTR may contribute to anti-HBs development (titre ≥ 10 IU/L) in HD patients either individually or jointly with the IL18 polymorphism.MethodsIn 518 HD patients and 240 controls the IL12A rs568408 3’UTR G > A polymorphism was genotyped by high-resolution melting curve analysis. Polymerase chain reaction restriction fragment length polymorphism was used to detect the IL12B rs3212227 3’UTR A > C and IL18 -1297 T > C rs360719 polymorphisms. The associations between the IL12A, IL12B and IL18 genotypes and the risk of impaired anti-HBs development were estimated by computing the odds ratios and their 95% confidence intervals using logistic regression analysis.ResultsIn the logistic regression analysis, the higher frequency of rs360719 CC individually (2.9% in 207 patients without anti-HBs development vs 8.0% in 311 patients with anti-HBs development, p = 0.009) and of rs360719 CC combined with rs568408 GG (p = 0.048), rs568408 GA (p = 0.035), rs568408 GG/AA (p = 0.034) or rs3212227 AA (p = 0.046) was associated with an increased chance for the development of anti-HBs in HD patients. Patients bearing both rs568408 AA and rs360719 TT had a 10.9-fold or 8.9-fold lower chance, respectively, to develop anti-HBs compared with those carrying any other genotype (p = 0.005) or those who had both wild-type rs568408 GG and rs360719 TT (p = 0.011). Carriers of both rs3212227 CC and rs360719 TC had a 4.6-fold lower chance for anti-HBs development than carriers of any other genotype (p = 0.042).ConclusionDevelopment of anti-HBs in HD patients is associated with gene polymorphisms of interleukins involved in the Th1 system.

Hepatitis B Vaccination in Chronic Kidney Disease: Review of Evidence in Non-Dialyzed Patients

“…In 1998 Hohler and et al (28) have reported enhanced expression of DRB 1×3, DRB 1×7 and DRB 1×14 in nonresponders to hepatitis B vaccine. More recently, interleukin genotypes (examples IL10, IL-12, IL-18) were associated with the anti-HBs development in response to HBsAg in HD patients (29-31). A very well established negative factor of immunization failure is increasing age (30, 32-34).…”

Spectrum of hepatitis B and renal involvement

“…Vaccination is important both to prevent susceptible patients from acquiring HBV and to reduce the pool of HBV‐infected patients. About 20% dialysis patients do not develop protective titre of antibodies to hepatitis virus surface antigen . Therefore, hepatitis B vaccination is suggested for patients with chronic kidney disease prior dialysis commencement when the immune system is less compromised which provides higher seroprotection rates and antibody titres .…”

Prophylactic vaccinations in chronic kidney disease: Current status

“…Results of these studies indicate that in renal replacement therapy (RRT) subjects, there is a relatively weak association between polymorphisms of genes encoding Th cell cytokines and development of antibodies to surface antigen of hepatitis B virus (anti-HBs) in response to hepatitis B vaccination or hepatitis B virus (HBV) infection. [25][26][27][28][29][30] Active immunization against HBV may be less effective in ESRD patients due to vitamin D deficiency. 31 Vitamin D related genetic background may contribute to lower response to hepatitis B vaccination.…”